Medical
-
Canadian biotech SaNOtize said that a Phase 2 trial of its nitric oxide nasal spray (NONS) in COVID-19 patients demonstrated that the nasal spray reduced viral load by about 95% within 24 hours post dose… Read more . . .
-
TFF Pharmaceuticals has announced agreements for feasibility studies with vaccine developer GreenLight Biosciences and with NeuroRx. TFF is performing studies to determine if dry powder formulations of GreenLight’s mRNA COVID-19 vaccine candidate and NeuroRx’s Zyesami… Read more . . .
-
The Lundquist Institute for Biomedical Innovation (TLI, formerly LABioMed) has licensed a dry powder synthetic lung surfactant formulation to The Bill & Melinda Gates Medical Research Institute (Gates MRI), TLI said. Gates MRI plans to develop… Read more . . .
-
AIM ImmunoTech announced that that the first subjects have been dosed in a Phase 1 safety study of an intranasal formulation of the company’s Ampligen rintatolimod, which the company is developing for the prevention and/or… Read more . . .
-
According to Pneumagen, its Neumifil carbohydrate binding module (mCBM), which it is developing as a nasal spray for the prevention and treatment of respiratory infections, significantly reduced symptoms and weight loss in a hamster model… Read more . . .
-
Pulmatrix has announced plans for clinical development of PUR3100, an iSPERSE dry powder formulation of dihydroergotamine (DHE) for the treatment of migraine, after a PK study in dogs showed exposure kinetics similar to those of… Read more . . .
-
Sorrento Therapeutics said that the FDA has cleared its IND for a Phase 1 study of STI-2099 intranasal neutralizing antibody (CoviDrops) in healthy volunteers and in patients with mild COVID-19. The company said that it… Read more . . .
-
Atossa Therapeutics announced that a two-week Phase 1 study evaluating the safety of two dose levels of the company’s AT-301 nasal spray in healthy volunteers demonstrated that the nasal spray was safe and well tolerated.… Read more . . .
-
Virpax Pharmaceuticals said that the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health has begun pre-clinical studies of Virpax’s Envelta intranasal enkephalin to support an IND submission. Virpax signed a cooperative… Read more . . .
-
Aridis Pharmaceuticals announced that it is now receiving preclinical support from the NIAID (National Institute of Allergy and Infectious Diseases) and CoVIC (Coronavirus Immunotherapy Consortium) for a nebulized monoclonal antibody cocktail for COVID-19 and that… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.